A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Study identifier:CD-ON-MEDI-551-1019

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

Medical condition

Chronic Lymphocytic Leukemia (CLL)

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI-551, Rituximab, Bendamustine

Sex

All

Actual Enrollment

183

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 01 Feb 2012
Primary Completion Date: 01 Jan 2016
Study Completion Date: 01 Jan 2016

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2016 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria